 Up to 50 patients with IBS will be recruited for the study. All patients will have an established diagnosis of IBS as per the Rome III criteria. Subjects will be recruited from the population of IBS patients attending Cork gastroenterology outpatients. Subjects will be randomly assigned to either the treatment group or placebo control group. 